Adaptive Biotechnologies Corp (NAS:ADPT)
$ 6.29 -0.15 (-2.33%) Market Cap: 950.41 Mil Enterprise Value: 791.33 Mil PE Ratio: 0 PB Ratio: 4.25 GF Score: 78/100

Adaptive Biotechnologies Corp at Cowen HealthCare Conference Transcript

Mar 03, 2020 / 01:40PM GMT
Release Date Price: $25.72 (-4.03%)
Doug Schenkel
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

All right. Good morning, everybody. It's our pleasure to welcome Chad Robins from Adaptive Biotechnologies to the Cowen Conference. Thanks for being here, Chad. Adaptive's immune profiling platform is well-validated and its product pipeline continues to advance. Chad and his team have successfully demonstrated their regulatory and reimbursement prowess via clonoSEQ and also via many clonoSEQ and immunoSEQ-related partnerships. Over the next 30 minutes or so, we're going to focus on the outlook for 2020, progress across the base business as well as pipeline developments and the associated time lines. So again, thanks, Chad, for joining us.

Chad M. Robins
Adaptive Biotechnologies Corporation - Co-Founder, CEO & Chairman

Thanks for having me here, Doug.

Questions & Answers

Doug Schenkel
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

I wanted to spend a few minutes just going back to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot